Last week, MannKind (NASDAQ:56400P706) announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months.
Investors seemed surprised, with shares falling 8% on Monday, although it made all that and more back in the following two days.
Despite issues with limited time between the advisory committee meeting and the FDA decision date as well as a controversy over conversion between inhaled Afrezza and its injected counterparts from Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), a majority of investors in a Motley Fool poll thought the FDA would approve Afrezza this week.
In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss the reason straw polls tend to be more positive than they probably should be, and they give their thoughts on the likelihood of approval by July 15.
Brian Orelli, Max Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.